Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 43%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is well positioned for success in the near-term with upcoming catalysts such as ESMO and TL1A readouts. The company also has a strong pipeline and potential for significant BD activity, providing opportunities for further growth. Merck has a diverse range of products in several therapeutic areas and a strong geographic presence in the US, making it a stable and well-established company in the pharmaceutical industry.

Bears say

Merck & Co is a global biopharmaceutical company that operates through two primary business segments, including research-based biopharmaceutical products and global contract manufacturing and animal health. Factors that could negatively impact the company's stock include slower than anticipated growth for new products, disappointing pipeline data results, successful challenges to key patents, delays in approval of investigational assets, and unfavorable macroeconomic conditions that lead to a market rotation away from defensive stocks. Furthermore, climate change and ESG concerns could lead to increased costs and regulatory pressures that may impact the company's business and reputation.

Merck (MRK) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 43% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 21 analysts, Merck (MRK) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $143.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $143.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.